IL10 and primary cutaneous T-cell non-Hodgkin lymphoma: Beyond cytotoxicity, they reduce IL-10 secretion via STAT3 inhibition in cutaneous T-cell lymphoma [45] and, in renal cancer models, decrease myeloid-derived suppressor cells while enhancing PD-1 blockade efficacy [46].